---
title: "Zepbound (tirzepatide), all indications: Safety questions"
description: "Safety questions on Zepbound (tirzepatide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings and Side effects. Questions: Can Zepbound cause severe stomach side effects? Can Zepbound be used with severe gastroparesis? Do antibodies to Zepbound affect how well it works? Does Zepbound cause thyroid cancer (boxed warning)? 8 further questions follow. 12 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/zepbound/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Zepbound (tirzepatide), all indications: Safety questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Zepbound](https://uspl.lilly.com/zepbound/zepbound.html#pi)  
Indication pages: [Chronic weight management](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management)

## Warnings

<a id="zepbound-severe-gi-gastroparesis"></a>

### Can Zepbound cause severe stomach side effects?

> “Use of ZEPBOUND has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (6)]. In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), severe gastrointestinal adverse reactions were reported more frequently among patients receiving ZEPBOUND (5 mg 1.7%, 10 mg 2.5%, 15 mg 3.1%) than placebo (1%). Similar rates of severe gastrointestinal adverse reactions were observed in ZEPBOUND clinical trials for weight reduction and in ZEPBOUND clinical trials for OSA. Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Use%20of%20ZEPBOUND%20has%20been,postmarketing%20with%20GLP%2D1%20receptor%20agonists.)

> “Gastrointestinal: acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Gastrointestinal%3A%20acute%20pancreatitis%2C%20hemorrhagic%20and,severe%20constipation%20including%20fecal%20impaction)

<a id="zepbound-gastroparesis"></a>

### Can Zepbound be used with severe gastroparesis?

> “ZEPBOUND is not recommended in patients with severe gastroparesis.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=GLP%2D1%20receptor%20agonists.-,ZEPBOUND%20is%20not%20recommended%20in%20patients%20with%20severe%20gastroparesis.)

<a id="zepbound-boxed-warning-thyroid"></a>

### Does Zepbound cause thyroid cancer (boxed warning)?

> “WARNING: RISK OF THYROID C-CELL TUMORS
> In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)].
> ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of ZEPBOUND and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with ZEPBOUND [see Contraindications (4) and Warnings and Precautions (5.1)].”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=WARNING%3A%20RISK%20OF%20THYROID%20C%2DCELL,and%20Warnings%20and%20Precautions%20%285.1%29%5D.)

> “Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with ZEPBOUND. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Routine%20monitoring%20of%20serum%20calcitonin%20or%20using%20thyroid%20ultrasound%20is%20of%20uncertain%20value%20for%20early%20detection%20of%20MTC%20in%20patients%20treated%20with%20ZEPBOUND.%20Such%20monitoring%20may%20increase%20the%20risk%20of%20unnecessary%20procedures%2C%20due%20to%20the%20low%20test%20specificity%20for%20serum%20calcitonin%20and%20a%20high%20background%20incidence%20of%20thyroid%20disease.%20Significantly%20elevated%20serum%20calcitonin%20values%20may%20indicate%20MTC%20and%20patients%20with%20MTC%20usually%20have%20calcitonin%20values%20%3E50%20ng%2FL.%20If%20serum%20calcitonin%20is%20measured%20and%20found%20to%20be%20elevated%2C%20the%20patient%20should%20be%20further%20evaluated.%20Patients%20with%20thyroid%20nodules%20noted%20on%20physical%20examination%20or%20neck%20imaging%20should%20also%20be%20further%20evaluated.,-5.2%20Severe%20Gastrointestinal)

> “A 2-year carcinogenicity study was conducted with tirzepatide in male and female rats at doses of 0.15, 0.50, and 1.5 mg/kg (0.1-, 0.4-, and 1-fold the MRHD of 15 mg once weekly based on AUC) administered by subcutaneous injection twice weekly. A statistically significant increase in thyroid C-cell adenomas was observed in male rats (≥0.5 mg/kg) and female rats (≥0.15 mg/kg), and a statistically significant increase in thyroid C-cell adenomas and carcinomas combined was observed in male and female rats at all doses examined. In a 6-month carcinogenicity study in rasH2 transgenic mice, tirzepatide at doses of 1, 3, and 10 mg/kg administered by subcutaneous injection twice weekly was not tumorigenic.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=A%202%2Dyear%20carcinogenicity%20study%20was,twice%20weekly%20was%20not%20tumorigenic.)

<a id="zepbound-contraindications"></a>

### Who should not take Zepbound?

> “ZEPBOUND is contraindicated in patients with:
>
> A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].
> Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide [see Warnings and Precautions (5.6) and Adverse Reactions (6.2)].”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=ZEPBOUND%20is%20contraindicated%20in%20patients%20with%3A,%285.6%29%20and%20Adverse%20Reactions%20%286.2%29%5D.)

<a id="zepbound-pancreatitis"></a>

### Can Zepbound cause pancreatitis?

> “Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or ZEPBOUND [see Adverse Reactions (6)].
>
> After initiation of ZEPBOUND, observe patients carefully for signs and symptoms of acute pancreatitis which may include persistent or severe abdominal pain (sometimes radiating to the back) and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue ZEPBOUND and initiate appropriate management.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Acute%20pancreatitis%2C%20including%20fatal%20and,ZEPBOUND%20and%20initiate%20appropriate%20management.)

> “In clinical trials of tirzepatide for a different indication, 14 events of acute pancreatitis were confirmed by adjudication in 13 tirzepatide-treated patients (0.23 patients per 100 years of exposure) versus 3 events in 3 comparator-treated patients (0.11 patients per 100 years of exposure). In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), 0.2% of ZEPBOUND-treated patients had acute pancreatitis confirmed by adjudication (0.14 patients per 100 years of exposure) versus 0.2% of placebo-treated patients (0.15 patients per 100 years of exposure).”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=In%20clinical%20trials%20of%20tirzepatide,%280.15%20patients%20per%20100%20years%20of%20exposure%29.)

> “In a pool of Study 1 and 2, treatment with ZEPBOUND resulted in mean increases from baseline in serum pancreatic amylase concentrations of 20% to 25% and serum lipase concentrations of 28% to 35%, compared to mean increases from baseline in pancreatic amylase of 2.1% and serum lipase of 5.8% in placebo-treated patients. The clinical significance of elevations in amylase or lipase with ZEPBOUND is unknown in the absence of other signs and symptoms of pancreatitis.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=and%20Lipase%20Increase-,In%20a%20pool%20of%20Study%201%20and%202%2C%20treatment%20with,signs%20and%20symptoms%20of%20pancreatitis.)

<a id="zepbound-gallbladder"></a>

### Can Zepbound cause gallbladder problems or gallstones?

> “Treatment with ZEPBOUND and GLP-1 receptor agonists is associated with an increased occurrence of acute gallbladder disease.
>
> In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), cholelithiasis was reported in 1.1% of ZEPBOUND-treated patients and 1% of placebo-treated patients, cholecystitis was reported in 0.7% of ZEPBOUND-treated patients and 0.2% of placebo-treated patients, and cholecystectomy was reported in 0.2% of ZEPBOUND-treated patients and no placebo-treated patients. Acute gallbladder events were associated with weight reduction. Similar rates of cholelithiasis were reported in ZEPBOUND clinical trials for weight reduction and in ZEPBOUND trials for OSA. If cholecystitis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Treatment%20with%20ZEPBOUND%20and%20GLP%2D1,appropriate%20clinical%20follow%2Dup%20are%20indicated.)

<a id="zepbound-hypoglycemia"></a>

### Can Zepbound cause low blood sugar (hypoglycemia)?

> “ZEPBOUND lowers blood glucose and can cause hypoglycemia.
>
> In a trial of patients with type 2 diabetes mellitus and BMI ≥27 kg/m2 (Study 2), hypoglycemia (plasma glucose <54 mg/dL) was reported in 4.2% of ZEPBOUND-treated patients versus 1.3% of placebo-treated patients. In this trial, patients taking ZEPBOUND in combination with an insulin secretagogue (e.g., sulfonylurea) had increased risk of hypoglycemia (10.3%) compared to ZEPBOUND-treated patients not taking a sulfonylurea (2.1%). There is also increased risk of hypoglycemia in patients treated with tirzepatide in combination with insulin [see Drug Interactions (7.1)].
>
> Hypoglycemia has also been associated with ZEPBOUND and GLP-1 receptor agonists in adults without type 2 diabetes mellitus [see Adverse Reactions (6.1)].
>
> Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. In patients with diabetes mellitus, monitor blood glucose prior to starting ZEPBOUND and during ZEPBOUND treatment. The risk of hypoglycemia may be lowered by a reduction in the dose of insulin or sulfonylurea (or other concomitantly administered insulin secretagogue).”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=ZEPBOUND%20lowers%20blood%20glucose%20and,other%20concomitantly%20administered%20insulin%20secretagogue%29.)

> “In Study 1, a trial of ZEPBOUND in adults with obesity/overweight without type 2 diabetes mellitus, there was no systematic capturing of hypoglycemia, but plasma glucose <54 mg/dL was reported in 0.3% of ZEPBOUND-treated patients versus no placebo-treated patients.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=In%20Study%201%2C%20a%20trial,patients%20versus%20no%20placebo%2Dtreated%20patients.)

<a id="zepbound-kidney"></a>

### Can Zepbound cause kidney problems?

> “There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or ZEPBOUND [see Adverse Reactions (6.2)]. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6.1)]. Monitor renal function in patients reporting adverse reactions to ZEPBOUND that could lead to volume depletion, especially during dosage initiation and escalation of ZEPBOUND.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=There%20have%20been%20postmarketing%20reports,initiation%20and%20escalation%20of%20ZEPBOUND.)

> “In a pool of Study 1 and 2, acute kidney injury was reported in 0.5% of ZEPBOUND-treated patients compared to 0.2% of placebo-treated patients.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=In%20a%20pool%20of%20Study%201%20and%202%2C%20acute,to%200.2%25%20of%20placebo%2Dtreated%20patients.)

> “Inform patients of the potential risk of acute kidney injury due to dehydration associated with gastrointestinal adverse reactions. Advise patients to take precautions to avoid fluid depletion. Inform patients of the signs and symptoms of acute kidney injury and instruct them to promptly report any of these signs or symptoms or persistent (or extended) nausea, vomiting, and diarrhea to their healthcare provider [see Warnings and Precautions (5.3)].”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Inform%20patients%20of%20the%20potential%20risk%20of%20acute,%5Bsee%20Warnings%20and%20Precautions%20%285.3%29%5D.)

<a id="zepbound-surgery-anesthesia"></a>

### Should Zepbound be stopped before surgery or anesthesia?

> “ZEPBOUND delays gastric emptying [see Clinical Pharmacology (12.2)]. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.
>
> Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking ZEPBOUND, including whether modifying preoperative fasting recommendations or temporarily discontinuing ZEPBOUND could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking ZEPBOUND.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=ZEPBOUND%20delays%20gastric%20emptying%20%5Bsee,if%20they%20are%20taking%20ZEPBOUND.)

<a id="zepbound-hypersensitivity"></a>

### Can Zepbound cause allergic reactions?

> “There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) in patients treated with tirzepatide. In a pool of two ZEPBOUND clinical studies for weight reduction (Studies 1 and 2), 0.1% of ZEPBOUND-treated patients had severe hypersensitivity reactions compared to no placebo-treated patients. Similar rates of severe hypersensitivity reactions were observed in ZEPBOUND clinical trials for weight reduction and in ZEPBOUND trials for OSA. If hypersensitivity reactions occur, advise patients to promptly seek medical attention and discontinue use of ZEPBOUND. Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in ZEPBOUND [see Contraindications (4) and Adverse Reactions (6.2)].
>
> Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 receptor agonists. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to these reactions with ZEPBOUND.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=There%20have%20been%20postmarketing%20reports%20of%20serious,to%20these%20reactions%20with%20ZEPBOUND.)

> “In a pool of Study 1 and 2, immediate hypersensitivity reactions (within one day after drug administration) occurred in 2.1% of ZEPBOUND-treated patients compared to 0.4% of placebo-treated patients, while non-immediate hypersensitivity reactions occurred in 3.5% of ZEPBOUND-treated patients compared to 2.7% of placebo-treated patients. Among ZEPBOUND-treated patients, hypersensitivity reactions were more frequent in those with anti-tirzepatide antibodies (6.2%) compared to those who did not develop anti-tirzepatide antibodies (3%) [see Clinical Pharmacology (12.6)]. The majority of the hypersensitivity reactions in trials were skin reactions (e.g., rash, itching).”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=In%20a%20pool%20of%20Study%201%20and%202%2C%20immediate,skin%20reactions%20%28e.g.%2C%20rash%2C%20itching%29.)

<a id="zepbound-diabetic-retinopathy"></a>

### Can Zepbound worsen diabetic retinopathy?

> “Temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Temporary%20worsening%20of%20diabetic%20retinopathy,for%20progression%20of%20diabetic%20retinopathy.)

> “Inform patients with type 2 diabetes mellitus to contact their healthcare provider if changes in vision are experienced during treatment with ZEPBOUND [see Warnings and Precautions (5.8)].”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Inform%20patients%20with%20type%202,%5Bsee%20Warnings%20and%20Precautions%20%285.8%29%5D.)

## Side effects

<a id="zepbound-antibodies"></a>

### Do antibodies to Zepbound affect how well it works?

> “The incidence of anti-drug antibodies (ADA) to ZEPBOUND was evaluated in adult patients with overweight or obesity or with OSA and obesity in clinical studies lasting 52 weeks or longer. Anti-tirzepatide antibodies were detected in 64.5% (1591/2467) of ZEPBOUND-treated patients in weight reduction clinical studies 1 and 2, and 60.6% (137/226) of ZEPBOUND-treated patients in OSA clinical studies [see Clinical Studies (14)].”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=The%20incidence%20of%20anti%2Ddrug%20antibodies%20%28ADA%29,studies%20%5Bsee%20Clinical%20Studies%20%2814%29%5D.)

> “No clinically significant effect of anti-tirzepatide antibodies on pharmacokinetics or effectiveness of ZEPBOUND has been identified. More ZEPBOUND-treated patients who developed anti-tirzepatide antibodies experienced hypersensitivity reactions or injection site reactions than those who did not develop these antibodies [see Adverse Reactions (6.1)].”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=No%20clinically%20significant%20effect%20of,antibodies%20%5Bsee%20Adverse%20Reactions%20%286.1%29%5D.)

## Related pages
- [Medical information: Zepbound (tirzepatide): All indications](https://www.evicenter.com/medical-information/zepbound)
- [Indication](https://www.evicenter.com/medical-information/zepbound/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/zepbound/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/zepbound/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/zepbound/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/zepbound/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/zepbound/storage-and-supply)
